Published online May 26, 2021. doi: 10.4330/wjc.v13.i5.130
Peer-review started: January 9, 2021
First decision: February 28, 2021
Revised: March 4, 2021
Accepted: April 28, 2021
Article in press: April 28, 2021
Published online: May 26, 2021
The overall risk assessment for coronary artery disease (CAD) in postmenopausal women cannot rely on traditional risk factors. Thus, assessment of novel markers is needed. Receptor for advanced glycation end products (RAGE) interaction is of great importance in diabetic vasculopathy and plays a key role in atherosclerosis.
The motivation was to add to what is known of the role of soluble fraction of RAGE (sRAGE) in Indian postmenopausal women.
The objective was to investigate the association and correlation between plasma levels of sRAGE and CAD in nondiabetic postmenopausal women.
This case-control study included 55 angiographically proven CAD subjects with > 50% stenosis of at least one of the major coronary arteries and 55 healthy control women. Plasma sRAGE was determined with an enzyme-linked immunosorbent assay.
Plasma sRAGE concentrations were significantly lower in subjects with CAD than it was in healthy controls. A significant correlation between plasma sRAGE levels and CAD was observed using univariate and multivariate analysis.
sRAGE was positively correlated with CAD independent of other traditional risk factors.
sRAGE can be included in the assessment of CAD-risk in postmenopausal women.